ArticleMedical care2014
Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage.
Article in Medical care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmaceutical policies: effects of regulating drug insurance schemes.The Cochrane database of systematic reviews · 2022Pooled it
- Discrepancies in Cardiovascular Disease Risk Perception Among African American Emerging Adults.Nursing (Auckland, N.Z.) · 2025Article
- Article
- The role of integrated medical and prescription drug plans in addressing racial and ethnic disparities in medication adherence.Journal of managed care & specialty pharmacy · 2022Article
- Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review.Public health reviews · 2022Article
- Patient preferences for medication adherence financial incentive structures: A discrete choice experiment.Research in social & administrative pharmacy : RSAP · 2021Article
- Association Between Medicaid Prescription Drug Limits and Access to Medications and Health Care Use Among Young Adults With Disabilities.JAMA health forum · 2021Article
- Perceived appropriateness of medication adherence incentives.Journal of managed care & specialty pharmacy · 2021Article
- Study protocol: Using peer support to aid in prevention and treatment in prediabetes (UPSTART).Contemporary clinical trials · 2020Article
- Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer.Journal of cancer survivorship : research and practice · 2018Article
- Counter-Point: Staying Honest When Policy Changes Backfire.Medical care · 2018Article
- Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017Article
- Trends in health care expenditure in U.S. adults with diabetes: 2002-2011.Diabetes care · 2015Article
- Effects of eliminating drug caps on racial differences in antidepressant use among dual enrollees with diabetes and depression.Clinical therapeutics · 2015Article
- Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.JAMA psychiatry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe use of lipid-lowering agents is suboptimal among dual enrollees, particularly blacks.
objectivesTo determine whether the removal of restrictive drug caps under Medicare Part D reduced racial differences among dual enrollees with diabetes. RESEARCH
designAn interrupted time series with comparison series design (ITS) cohort study. SUBJECTS: A total of 8895 black and white diabetes patients aged 18 years and older drawn from a nationally representative sample of fee-for-service dual enrollees (January 2004-December 2007) in states with and without drug caps before Part D. MEASURES: We examined the monthly (1) proportion of patients with any use of lipid-lowering therapies; and (2) intensity of use. Stratification measures included age (less than 65, 65 y and older), race (white vs. black), and sex.
resultsAt baseline, lipid-lowering drug use was higher in no drug cap states (drug cap: 54.0% vs. nondrug cap: 66.8%) and among whites versus blacks (drug cap: 58.5% vs. 44.9%, no drug cap: 68.4% vs. 61.9%). In strict drug cap states only, Part D was associated with an increase in the proportion with any use [nonelderly: +0.07 absolute percentage points (95% confidence interval, 0.06-0.09), P<0.001; elderly: +0.08 (0.06-0.10), P<0.001] regardless of race. However, we found no evidence of a change in the white-black gap in the proportion of users despite the removal of a significant financial barrier.
conclusionsMedicare Part D was associated with increased use of lipid-lowering drugs, but racial gaps persisted. Understanding non-coverage-related barriers is critical in maximizing the potential benefits of coverage expansions for disparities reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.